Top Markets
Coin of the day
PaxMedica, Inc. Common Stock PaxMedica, Inc. Common Stock

PaxMedica, Inc. Common Stock

PXMD
株式のランク #40913
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical... PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.
株価
$0.0005
最終同期: 2026-08-12
時価総額
$63.13K
変化(1日)
0.00%
変化(1年)
150.00%
US
取引 PaxMedica, Inc. Common Stock (PXMD)

カテゴリー

PaxMedica, Inc. Common Stock(PXMD)の配当履歴
PaxMedica, Inc. Common Stock(証券コード:PXMD)は合計で0回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:0.00
配当利回り(TTM):0
2026から2026までのPaxMedica, Inc. Common Stock(PXMD)の配当履歴
年間配当支払い
配当(株式分割調整済み) 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴